Procter & Gamble Hygiene and Health Care Ltd
Procter & Gamble Hygiene and Health Care Limited is engaged in the manufacturing and selling of branded packaged fast moving consumer goods in the femcare and healthcare businesses. Its portfolio includes WHISPER – India’s leading Feminine Hygiene brand, and VICKS – India’s No. 1 Health Care brand and Old Spice.
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
- +Company has a good return on equity (ROE) track record: 3 Years ROE 78.6%
- +Company has been maintaining a healthy dividend payout of 89.3%
Weaknesses
- −Stock is trading at 33.1 times its book value
- −The company has delivered a poor sales growth of 2.75% over past five years.
Shareholding Pattern
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.64% | 70.64% | 70.64% | 70.64% | 70.64% | 70.64% | 70.64% | 70.64% |
| FIIs | 1.56% | 1.48%▼0.1 | 1.43%▼0.1 | 1.33%▼0.1 | 1.38%▲0.0 | 1.11%▼0.3 | 1.06%▼0.1 | 0.97%▼0.1 |
| DIIs | 15.16% | 15.28%▲0.1 | 15.37%▲0.1 | 15.5%▲0.1 | 15.49%▼0.0 | 16.05%▲0.6 | 16.03%▼0.0 | 15.96%▼0.1 |
| Public | 12.65% | 12.6%▼0.1 | 12.56%▼0.0 | 12.52%▼0.0 | 12.48%▼0.0 | 12.19%▼0.3 | 12.25%▲0.1 | 12.43%▲0.2 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,138 | 1,133 | 1,002 | 932 | 1,135 | 1,248 | 992 | 937 | 1,150 | 1,262 |
| Expenses | 853 | 824 | 745 | 813 | 845 | 877 | 782 | 671 | 865 | 860 |
| Operating Profit | 285 | 310 | 257 | 118 | 290 | 371 | 210 | 266 | 285 | 402 |
| OPM % | 25% | 27% | 26% | 13% | 26% | 30% | 21% | 28% | 25% | 32% |
| Net Profit | 211 | 229 | 154 | 81 | 212 | 269 | 156 | 192 | 210 | 301 |
| EPS ₹ | 64.91 | 70.52 | 47.56 | 24.97 | 65.28 | 82.74 | 48.09 | 59.17 | 64.65 | 92.87 |
AI Insights
TTM revenue at ₹4,341Cr, up 28.7% YoY. OPM at 27%.
Borrowings at ₹2Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
CWIP at ₹14Cr (8% of fixed assets). Moderate ongoing capital expenditure.
DIIs: 15.96% (+0.47pp change). FIIs: 0.97% (-0.16pp change). Promoters hold 70.64%.
ROCE improving from 52% (Jun 2014) to 104% (Mar 2025). Working capital days: -31.
PE 36.5x with 104% ROCE. Price is 3268% above book value of ₹287. Dividend yield: 1.74%.
Recent Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Apr - Company has submitted Certificate under regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026
- Intimation Regarding Ease Of Doing Business - Special Window For Transfer And Dematerialization Of Physical Securities 7 Apr - SEBI special window for re-lodgement of physical shares extended to February 4, 2027.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 6 Apr - Company says it is not a SEBI Large Corporate; outstanding borrowing was nil on March 31, 2026.
- Board Meeting Intimation for Board Meeting Scheduled To Be Held On May 28, 2026 27 Mar - Board meeting scheduled May 28, 2026 to consider audited FY2026 financials and possible final dividend.
- Closure of Trading Window 27 Mar - Trading window closed for directors/designated employees from April 1, 2026 until 48 hours after audited FY2026 results publication.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse